Annovis Bio has reported new biomarker findings from its Phase 3 trial in early Parkinson’s disease, showing that roughly 25 percent of participants exhibited amyloid (Alzheimer’s-type) co-pathology—and these individuals experienced markedly faster cognitive decline compared to those without. According to the company, treatment with its drug buntanetap not only halted this accelerated decline but reversed it in this subgroup, suggesting a differentiated and enhanced effect.
In addition to clinical improvement, the data revealed significant reductions in plasma biomarkers closely associated with neurodegeneration—namely pTau217, total tau, and brain-derived (BD) tau—after buntanetap treatment. These changes, the company said, support the idea that the drug may be modulating disease drivers common to multiple proteinopathies.
Annovis argued that these findings reinforce its therapeutic rationale: neurodegenerative diseases like Alzheimer’s and Parkinson’s often involve overlapping pathology, and a drug capable of targeting multiple toxic proteins may offer broader disease-modifying benefits. The full dataset is scheduled for presentation at the upcoming CTAD (Clinical Trials on Alzheimer’s Disease) conference in December 2025.
